Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrogel is an over-the-counter oral liquid antacid combination formulation containing dried aluminium hydroxide gel, magnesium trisilicate, and magnesium hydroxide. It is manufactured by Aspen Pharma and distributed by Arrotex Pharmaceuticals (and previously Viatris) in Australia. Gastrogel works by chemically neutralizing gastric acid in the stomach, thereby raising gastric pH to provide rapid relief from symptoms of dyspepsia, indigestion, heartburn, epigastric pain, and upset stomach. In the Royal Melbourne Hospital's COOLAID clinical trial, Gastrogel monotherapy was evaluated against combinations of Gastrogel with oral lidocaine (viscous or solution) for the treatment of acute epigastric pain and dyspepsia in the emergency department. The trial demonstrated that antacid monotherapy with Gastrogel was equally effective in pain relief compared to the lidocaine combinations, while being significantly more palatable and better tolerated by patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gastrogel.